These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 6936969)

  • 1. Antileukemic activity of 4-demethoxydaunorubicin in mice.
    Casazza AM; Pratesi G; Giuliani F; Di Marco A
    Tumori; 1980 Oct; 66(5):549-64. PubMed ID: 6936969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of SC33428, a novel bishydrazone-bridged derivative of 4-demethoxydaunorubicin, against experimental tumors in mice.
    Dawson KM
    Cancer Res; 1983 Jun; 43(6):2880-3. PubMed ID: 6573953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of various substitutions in positions 1, 2, 3, and 4 of 4-demethoxydaunorubicin and 4-demethoxyadriamycin.
    Di Marco A; Casazza AM; Soranzo C; Pratesi G
    Cancer Chemother Pharmacol; 1978; 1(4):249-54. PubMed ID: 750112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of the anthracycline agent, 7-con-O-methylnogarol (7-OMEN), administered orally to mice bearing P388 or L1210 leukemia.
    McGovren JP
    Cancer Treat Rep; 1980; 64(4-5):727-9. PubMed ID: 6448690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of 4-demethoxydaunorubicin administered orally.
    Di Marco A; Casazza AM; Pratesi G
    Cancer Treat Rep; 1977 Aug; 61(5):893-4. PubMed ID: 890695
    [No Abstract]   [Full Text] [Related]  

  • 6. Synthesis and antileukemic activity of N-enamine derivatives of daunorubicin, 5-iminodaunorubicin, and doxorubicin.
    Stefańska B; Dzieduszycka M; Bontemps-Gracz M; Borowski E; Martelli S
    J Antibiot (Tokyo); 1988 Feb; 41(2):193-8. PubMed ID: 3356607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their beta anomers.
    Arcamone F; Bernardi L; Giardino P; Patelli B; Marco A; Casazza AM; Pratesi G; Reggiani P
    Cancer Treat Rep; 1976 Jul; 60(7):829-34. PubMed ID: 1009518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies.
    Ganzina F; Pacciarini MA; Di Pietro N
    Invest New Drugs; 1986; 4(1):85-105. PubMed ID: 3516918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Models of preclinical studies of anthracyclines].
    Fizames C
    Pathol Biol (Paris); 1987 Jan; 35(1):41-8. PubMed ID: 3550611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor activity of daunorubicin linked to poly-L-aspartic acid.
    Zunino F; Giuliani F; Savi G; Dasdia T; Gambetta R
    Int J Cancer; 1982 Oct; 30(4):465-70. PubMed ID: 7141741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antitumor activities of orally administered 7-con-0-methylnogarol (TUT-7)].
    Sugimoto Y; Matsuo K; Takeda S; Yamada Y; Tsukagoshi S
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):353-8. PubMed ID: 2138003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and antitumor activity of novel 4-demethoxyanthracyclines.
    Adams N; Blake C; Broadhurst MJ; Bushnell DJ; Hassall CH; Hartmann HR; Keech E; Stratton AR; Thomas GJ
    J Med Chem; 1990 Sep; 33(9):2375-9. PubMed ID: 2391681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
    Tsuruo T; Oh-Hara T; Sudo Y; Naito M
    Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
    Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorescence assay of tissue distribution of 4-demethoxydaunorubicin and 4-demethoxydoxorubicin in mice bearing solid tumors.
    Formelli F; Casazza AM; Di Marco A; Mariani A; Pollini C
    Cancer Chemother Pharmacol; 1979; 3(4):261-9. PubMed ID: 294954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effect of selected daunorubicin derivatives in mice with P 388 leukemia.
    Kuśnierczyk H; Rak J; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1986; 34(3):259-62. PubMed ID: 3592929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro.
    Szmigielska-Kaplon A; Ciesielska E; Szmigiero L; Robak T
    Eur J Haematol; 2002 Jun; 68(6):370-5. PubMed ID: 12225395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and antitumor activity of optically active (+)-9-O-alpha-L-daunosaminyl-4-demethoxydaunorubicin.
    Kimura Y; Matsumoto T; Suzuki M; Terashima S
    J Antibiot (Tokyo); 1985 Sep; 38(9):1277-9. PubMed ID: 4066509
    [No Abstract]   [Full Text] [Related]  

  • 19. Synthesis and antitumor activity of 3'-C-methyl-daunorubicin.
    Thang TT; Imbach JL; Fizames C; Lavelle F; Ponsinet G; Olesker A; Lukacs G
    Carbohydr Res; 1985 Jan; 135(2):241-7. PubMed ID: 3986844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness of the anthracycline analog 4'-epidoxorubicin in the treatment of experimental tumors: a review.
    Goldin A; Venditti JM; Geran R
    Invest New Drugs; 1985; 3(1):3-21. PubMed ID: 3886588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.